Peachstate Health Management LLC

Peachstate Health Management LLC was paid $5.84M by Medicaid between Jan 2018 and Oct 2024, across 124 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 10% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Georgia

Rank by total paid#10 of 66

Median peer was paid$178K

This provider vs. median33×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	512,009	$3.34M
2019	318,000	$1.62M
2020	191,067	$554K
2021	19,510	$183K
2022	3,886	$73K
2023	845	$17K
2024incomplete	2,511	$51K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	10%	10,629	9,015	$591K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	7.7%	18,062	12,152	$449K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	6.2%	29,628	15,202	$360K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.1%	17,407	10,079	$356K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	3.6%	3,175	1,414	$207K
80346		3.0%	38,301	23,426	$173K
80337		2.9%	21,576	11,466	$168K
80372		2.9%	26,916	13,800	$167K
80376		2.6%	21,473	11,373	$154K
80354		2.6%	37,692	23,112	$153K
80367		2.6%	22,167	12,028	$150K
80357		2.6%	21,484	11,386	$150K

112 more codes

80332		2.6%	23,981	$149K
80368		2.5%	26,233	$147K
80345		2.5%	35,233	$145K
80361		2.5%	41,804	$144K
80364		2.3%	23,850	$137K
80321		2.3%	38,552	$137K
83992		2.1%	36,341	$124K
80373		2.1%	36,649	$122K
80369		2.0%	21,923	$117K
80323		2.0%	35,881	$116K
80365		1.9%	36,682	$114K
80338		1.9%	32,573	$113K
80355		1.9%	34,617	$111K
80353		1.8%	37,528	$108K
80358		1.8%	40,438	$103K
80366		1.8%	32,639	$102K
80348		1.7%	41,532	$99K
80324		1.6%	32,678	$96K
80360		1.6%	33,111	$91K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.2%	3,179	$68K
80349		<1%	17,404	$33K
80356		<1%	18,916	$33K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	449	$33K
81479	Unlisted molecular pathology procedure	<1%	47	$32K
80359		<1%	16,527	$32K
87913		<1%	164	$27K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,563	$27K
80362		<1%	7,676	$26K
80335		<1%	3,521	$17K
80370		<1%	8,458	$16K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	837	$15K
80363		<1%	8,147	$12K
80375		<1%	968	$11K
80350		<1%	733	$10K
81401		<1%	37	$6K
80340		<1%	7,256	$6K
81402		<1%	25	$5K
87631		<1%	179	$5K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	74	$5K
80325		<1%	6,235	$5K
87522	Neg quan hep c or qual rna	<1%	161	$5K
80336		<1%	5,258	$4K
80334		<1%	5,244	$3K
87483		<1%	51	$3K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	279	$3K
81226		<1%	38	$3K
84702		<1%	357	$3K
81291		<1%	24	$2K
87581		<1%	237	$2K
87486		<1%	237	$2K
81241		<1%	24	$2K
81240		<1%	24	$2K
87541		<1%	214	$2K
82570		<1%	5,823	$2K
81225		<1%	38	$2K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	14	$2K
80322		<1%	94	$2K
80053	Comprehensive metabolic panel	<1%	269	$1K
87653		<1%	284	$1K
80329		<1%	313	$1K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	182	$1K
87640		<1%	251	$1K
86705		<1%	161	$1K
86709		<1%	158	$1K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	260	$1K
84311		<1%	4,939	$1K
80339		<1%	262	$663.20
86702		<1%	65	$606.20
86703		<1%	72	$580.19
86684		<1%	164	$572.55
83986		<1%	4,356	$570.57
81025		<1%	160	$569.66
81003		<1%	1,568	$524.00
80061	Lipid panel	<1%	97	$492.77
87340		<1%	69	$460.10
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	88	$459.96
87496		<1%	35	$435.92
86701		<1%	65	$383.49
80050	General health panel	<1%	21	$348.14
81227		<1%	25	$326.05
82607		<1%	56	$274.25
80371		<1%	1,528	$255.91
82746		<1%	53	$252.40
81231		<1%	25	$218.46
83036	Hemoglobin; glycosylated (A1C)	<1%	88	$217.93
83540		<1%	83	$183.74
80074		<1%	13	$182.32
84481		<1%	41	$176.28
81355		<1%	24	$144.94
84439		<1%	66	$140.60
87481		<1%	57	$112.02
84443	Thyroid stimulating hormone (TSH)	<1%	35	$101.67
83970		<1%	14	$67.10
84403		<1%	30	$56.69
83001		<1%	15	$49.33
83002		<1%	15	$49.15
82670		<1%	14	$45.41
83721		<1%	13	$37.12
82627		<1%	15	$36.15
84270		<1%	14	$34.01
84681		<1%	14	$33.84
84144		<1%	14	$33.04
83525		<1%	16	$31.28
82533		<1%	15	$26.50
83550		<1%	16	$23.92
82728		<1%	15	$22.17
80333		<1%	38	$10.62
82150		<1%	14	$10.54
83735		<1%	14	$10.41
87641		0%	14	$0.00
87400		0%	164	$0.00
87807		0%	164	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLAPRISE, DEREK (CEO)